NO20060080L - Pyrrol-2,5-ditionderivater som Lever X reseptormodulatorer - Google Patents

Pyrrol-2,5-ditionderivater som Lever X reseptormodulatorer

Info

Publication number: NO20060080L
Authority: NO; Norway
Prior art keywords: liver; dition; pyrrole; derivatives; receptor modulators
Prior art date: 2003-07-11

Application number

NO20060080A

Other languages

English (en)

Norwegian (no)

Inventor

Patrik Holm

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-07-11

Filing date

2006-01-05

Publication date

2006-02-08

2006-01-05 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2006-02-08 Publication of NO20060080L publication Critical patent/NO20060080L/no

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Pyrrole Compounds (AREA)

NO20060080A 2003-07-11 2006-01-05 Pyrrol-2,5-ditionderivater som Lever X reseptormodulatorer NO20060080L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0316237.7A GB0316237D0 (en)	2003-07-11	2003-07-11	Therapeutic agents
PCT/SE2004/001115 WO2005005416A1 (en)	2003-07-11	2004-07-08	Pyrrole-2, 5-dithione derivatives as liver x receptor modulators

Publications (1)

Publication Number	Publication Date
NO20060080L true NO20060080L (no)	2006-02-08

Family

ID=27741986

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20060080A NO20060080L (no)	2003-07-11	2006-01-05	Pyrrol-2,5-ditionderivater som Lever X reseptormodulatorer

Country Status (25)

Country	Link
US (1)	US20060189663A1 (is)
EP (1)	EP1646625B1 (is)
JP (1)	JP2007521313A (is)
KR (1)	KR20060034284A (is)
CN (1)	CN100478340C (is)
AR (1)	AR045720A1 (is)
AT (1)	ATE399776T1 (is)
AU (1)	AU2004256000B2 (is)
BR (1)	BRPI0412479A (is)
CA (1)	CA2532068A1 (is)
CO (1)	CO5640134A2 (is)
DE (1)	DE602004014772D1 (is)
ES (1)	ES2308205T3 (is)
GB (1)	GB0316237D0 (is)
IL (1)	IL172759A0 (is)
IS (1)	IS8291A (is)
MX (1)	MXPA06000447A (is)
NO (1)	NO20060080L (is)
RU (1)	RU2006102129A (is)
SA (1)	SA04250203B1 (is)
TW (1)	TW200507836A (is)
UA (1)	UA82108C2 (is)
UY (1)	UY28407A1 (is)
WO (1)	WO2005005416A1 (is)
ZA (1)	ZA200600229B (is)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE0500058D0 (sv) *	2005-01-10	2005-01-10	Astrazeneca Ab	Therapeutic agents 5
SE0500055D0 (sv)	2005-01-10	2005-01-10	Astrazeneca Ab	Therapeutic agents 3
KR20070094963A (ko)	2005-01-10	2007-09-27	아스트라제네카 아베	간 ｘ 수용체 조절제로서 이소티아졸-3(2ｈ)-온1,1-디옥사이드 유도체
EP1907564B1 (en) *	2005-06-28	2013-10-23	Daiichi Sankyo Company, Limited	Lxr ligand testing method
EP2069359B1 (en)	2006-08-21	2014-11-12	Genentech, Inc.	Aza-benzothiophenyl compounds and methods of use
WO2008046014A1 (en)	2006-10-12	2008-04-17	Remedy Pharmaceuticals, Inc.	Treatment of alzheimer's disease using compounds that reduce the activity of non-selective ca++- activated atp-sensitive cation channels regulated by sur1 receptors
US10004703B2 (en)	2006-10-12	2018-06-26	Biogen Chesapeake Llc	Treatment of alzheimer's disease using compounds that reduce the activity of non-selective CA++ activated ATP-sensitive cation channels regulated by SUR1 channels
WO2008103818A1 (en) *	2007-02-21	2008-08-28	University Of Louisville Research Foundation	Therapeutic cotinine compositions
JP5812318B2 (ja)	2007-12-04	2015-11-11	レメディーファーマシューティカルズ，インコーポレイテッド	凍結乾燥のための改良された処方物および方法ならびにそれによって提供される凍結乾燥物
WO2009097443A2 (en)	2008-01-29	2009-08-06	Remedy Pharmaceuticals, Inc.	Liquid formulations of compounds active at sulfonylurea receptors
WO2010003025A1 (en)	2008-07-01	2010-01-07	Genentech, Inc.	Bicyclic heterocycles as mek kinase inhibitors
JP5615274B2 (ja)	2008-07-01	2014-10-29	ジェネンテック，インコーポレイテッド	Ｍｅｋキナーゼインヒビターとしてのイソインドロン誘導体及びその使用方法
CA2811145A1 (en)	2010-09-07	2012-03-15	Snu R&Db Foundation	Sesterterpene compound and use thereof
EP3091970B1 (en)	2014-01-10	2020-10-28	Rgenix, Inc.	Lxr agonists and uses thereof
US11648220B2 (en)	2016-01-11	2023-05-16	The Rockefeller University	Methods for the treatment of myeloid derived suppressor cells related disorders
AU2018373028A1 (en)	2017-11-21	2020-04-30	Inspirna, Inc.	Polymorphs and uses thereof
KR200492570Y1 (ko)	2018-12-04	2020-11-05	박규환	조립식 계단장치를 위한 발판
EP4073025B1 (en)	2019-12-13	2024-03-27	Inspirna, Inc.	Metal salts and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2002527419A (ja) *	1998-10-08	2002-08-27	スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー	Ｇｓｋ−３阻害物質としてのピロール−２，５−ジオン類
EP1212065A4 (en) *	1999-07-08	2004-02-11	Tularik Inc	COMPILATIONS AND METHODS FOR INCREASING THE HDL CHOLESTEROL LEVEL

2003
- 2003-07-11 GB GBGB0316237.7A patent/GB0316237D0/en not_active Ceased
2004
- 2004-06-29 TW TW093119119A patent/TW200507836A/zh unknown
- 2004-07-05 SA SA4250203A patent/SA04250203B1/ar unknown
- 2004-07-08 WO PCT/SE2004/001115 patent/WO2005005416A1/en not_active Ceased
- 2004-07-08 RU RU2006102129/04A patent/RU2006102129A/ru not_active Application Discontinuation
- 2004-07-08 KR KR1020067000616A patent/KR20060034284A/ko not_active Withdrawn
- 2004-07-08 CN CNB2004800197194A patent/CN100478340C/zh not_active Expired - Fee Related
- 2004-07-08 ES ES04749151T patent/ES2308205T3/es not_active Expired - Lifetime
- 2004-07-08 AT AT04749151T patent/ATE399776T1/de not_active IP Right Cessation
- 2004-07-08 JP JP2006520139A patent/JP2007521313A/ja not_active Withdrawn
- 2004-07-08 BR BRPI0412479-0A patent/BRPI0412479A/pt not_active IP Right Cessation
- 2004-07-08 AU AU2004256000A patent/AU2004256000B2/en not_active Ceased
- 2004-07-08 CA CA002532068A patent/CA2532068A1/en not_active Abandoned
- 2004-07-08 EP EP04749151A patent/EP1646625B1/en not_active Expired - Lifetime
- 2004-07-08 MX MXPA06000447A patent/MXPA06000447A/es not_active Application Discontinuation
- 2004-07-08 US US10/563,676 patent/US20060189663A1/en not_active Abandoned
- 2004-07-08 DE DE602004014772T patent/DE602004014772D1/de not_active Expired - Fee Related
- 2004-07-08 AR ARP040102418A patent/AR045720A1/es not_active Application Discontinuation
- 2004-07-09 UY UY28407A patent/UY28407A1/es unknown
- 2004-08-07 UA UAA200600270A patent/UA82108C2/uk unknown
2005
- 2005-12-22 IL IL172759A patent/IL172759A0/en unknown
2006
- 2006-01-05 NO NO20060080A patent/NO20060080L/no not_active Application Discontinuation
- 2006-01-10 ZA ZA200600229A patent/ZA200600229B/xx unknown
- 2006-01-20 CO CO06005238A patent/CO5640134A2/es not_active Application Discontinuation
- 2006-02-09 IS IS8291A patent/IS8291A/is unknown

Also Published As

Publication number	Publication date
CN1820003A (zh)	2006-08-16
CO5640134A2 (es)	2006-05-31
WO2005005416A1 (en)	2005-01-20
GB0316237D0 (en)	2003-08-13
IS8291A (is)	2006-02-09
EP1646625A1 (en)	2006-04-19
RU2006102129A (ru)	2006-08-27
ES2308205T3 (es)	2008-12-01
SA04250203B1 (ar)	2008-02-25
IL172759A0 (en)	2006-04-10
ATE399776T1 (de)	2008-07-15
JP2007521313A (ja)	2007-08-02
TW200507836A (en)	2005-03-01
UA82108C2 (uk)	2008-03-11
CA2532068A1 (en)	2005-01-20
AR045720A1 (es)	2005-11-09
HK1088318A1 (en)	2006-11-03
MXPA06000447A (es)	2006-04-07
CN100478340C (zh)	2009-04-15
UY28407A1 (es)	2005-02-28
KR20060034284A (ko)	2006-04-21
DE602004014772D1 (de)	2008-08-14
AU2004256000B2 (en)	2007-07-26
AU2004256000A1 (en)	2005-01-20
ZA200600229B (en)	2007-04-25
EP1646625B1 (en)	2008-07-02
US20060189663A1 (en)	2006-08-24
BRPI0412479A (pt)	2006-09-19

Legal Events

Date	Code	Title	Description
2009-02-23	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20073250L (no)	2007-07-19	Non-anilinderivater av isotiazol-3- (2H)-on 1,1-dioksider som lever-X-reseptor modulerende forbindelser.
NO20060081L (no)	2006-02-08	Pyrrol-2,5-dionderivater som lever X reseptormodulatorer
WO2007050726A3 (en)	2007-08-30	Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists
NO20073248L (no)	2007-10-01	Derivater av isotiazol-3(2H)-on 1,1-dioksider som lever X reseptor modulatorer
CN104995176B (zh)	2019-02-22	调节bace所介导的app加工的乙内酰脲
NO20071577L (no)	2007-05-02	Bifenyloksyiddiksyrederivater for behandling av luftveissykdommer
WO2009009501A3 (en)	2009-04-02	Non-basic melanin concentrating hormone receptor-1 antagonists and methods
WO2007082808A3 (en)	2007-09-13	Thiazoles as 11 beta-hsd1 inhibitors
CN102093246B (zh)	2014-10-29	酯类化合物、其制备方法和应用
NO20085271L (no)	2009-01-06	Muscarin reseptoragonister som er effektive i behandling av smerte, Alzheimers sykdom og schizofreni
CN102137858A (zh)	2011-07-27	5-脂氧合酶-活化蛋白抑制剂
WO2008131469A3 (de)	2009-04-23	Verfahren zur herstellung von hoch reinem 2,4 '-dimethyl-3-piperidino-propiophenon (tolperison), dieses enthaltende pharmazeutische zusammensetzungen, sowie tolperison enthaltende wirkstoffformulierungen
TW200507836A (en)	2005-03-01	Therapeutic agents
Al-Masri et al.	2024	Antidiabetic effect of flavonoid from Rumex vesicarius on alloxan induced diabetes in male albino Wistar rats and its validation through in silico molecular docking and dynamic simulation studies
CN103040779A (zh)	2013-04-17	用于神经系统疾病的口服固体药物组合物
EP1435353A1 (en)	2004-07-07	Novel heterocyclic compound and anti-inflammatory agent
EP2412705B1 (en)	2014-05-07	Novel therapeutic agent for cognitive impairment
JP7841019B2 (ja)	2026-04-06	ナツメ属植物及びガラナの生物活性植物化学物質
SE0500056D0 (sv)	2005-01-10	Therapeutic agents 4
NO20065501L (no)	2007-01-30	Lxr reseptor modulstorer.
CN108685928A (zh)	2018-10-23	毛壳素在制备治疗肝纤维化药物中的应用
Zhang et al.	2022	Discovery of potent glucokinase and PPARγ dual-target agonists through an innovative scheme for regioselective modification of silybin
SE0500058D0 (sv)	2005-01-10	Therapeutic agents 5
Sauerberg et al.	2005	Structure–activity relationships of dimeric PPAR agonists
AU646240B2 (en)	1994-02-17	4,4'-{9H-fluoren-9-ylidenebis(methylene)}-bispyrimidine for treating neurological disorders